SAN FRANCISCO — Lawyers from Cooley in San Diego and Palo Alto are advising pharmaceutical company Cypress Bioscience Inc., in its acquisition by Ramius LLC and Royalty Pharma.
The deal, valued at about $225 million in cash, ends a takeover battle that began in July. Under the terms, hedge fund Ramius will buy all of the Cypress shares it doesn’t already own for $6.50 a share. On Tuesday, Cypress had rejected a $6-per-share cash offer by Ramius, which had originally offered to buy Cypress for $4 a share in July.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
